Birzeit Pharmaceutical Co (XPAE:BPC) Tariff Resilience Score: 0/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:BPC Birzeit Pharmaceutical Co XPAE:BPC
91 GF Score
Price $3.67
GF Value $4.59
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Birzeit Pharmaceutical Co Tariff Resilience Score?

Birzeit Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Birzeit Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Birzeit Pharmaceutical Co might have .

Birzeit Pharmaceutical Co  (XPAE:BPC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Birzeit Pharmaceutical Co Tariff Resilience Score Related Terms

XPAE:BPC
91GF Score
Birzeit Pharmaceutical Co XPAE:BPC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?

Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued. The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59. GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for XPAE:BPC:

  • Tariff Resilience Score: 0
  • GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Birzeit Pharmaceutical Co Business Description

Address 20 Shatella Street, Betunia Industrial Area, Ramallah, PSE
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score

Get the complete analysis for XPAE:BPC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.67
Price
$4.59
GF Value